HOME : SITE MAP : HELP : CONTACT US : MEDIA : MISSION

CCSG Home

Administration

Director's Translational Research Initiative

Year 2006

Year 2007

Year 2008

Internal Advisory Board

Links

Meetings

Membership

Membership Directory

Pilot Projects

Programs

Shared Resources

Huntsman Cancer Institute demonstrates its continuing commitment to translational research with the first Director’s Translational Research Initiative. This annual program has the following specific goals:

  • to promote collaborative scientific interaction between basic and clinical investigators within HCI and the University of Utah
  • to provide assistance for investigators seeking rapid clinical translation of novel basic and preclinical observations
  • to engage clinical investigators with appropriate basic or technologic science expertise to investigate novel cellular, molecular, histopathologic, and imaging strategies in conjunction with HCI clinical trials

In fall 2005, cancer investigators from a variety of disciplines, including members of the five CCSG programs and of the Multidisciplinary Groups, submitted 28 proposals involving more than 60 researchers from throughout the University of Utah. Six proposals received funding under this program.

Cyclooxygenase-2 expression as a therapeutic target in meningiomas

Principal Investigator: William Couldwell, MD, PhD

Department: Neurosurgery

Collaborators: John Hoffman, MD; Randy Jensen, MD, PhD; Stephen Prescott, MD

Clinical and molecular pharmacology of Zileuton (ZyFLO) in pancreatic cancer

Principal Investigator: Frank Fitzpatrick, PhD

Department: Oncological Sciences

Collaborators: Wallace Akerley, MD; Matt Firpo, PhD; Sean Mulvihill, MD; Courtney Scaife, MD

NF-κB inhibitors are a novel class of drugs that may prevent cancer seeding and metastasis in humans

Principal Investigator: Scott Kuwada, MD

Department: Internal Medicine, Gastroenterology

Collaborators: Glenn Prestwich, PhD; Courtney Scaife, MD

The role of Notch signaling in pancreatic cancer

Principal Investigator: L. Charles Murtaugh, PhD

Department: Human Genetics

Epigenetic potentiation of Interferon-a using the DNA methylation inhibitor Decitabine: A Phase I study with molecular correlates

Principal Investigator: Wolfram Samlowski, MD

Department: Internal Medicine, Oncology

Collaborators: Wallace Akerley, MD; Ken Boucher, PhD; Frank Fitzpatrick, PhD; Gina Gregovich; Sancy Leachman, MD, PhD; Mark Wade, PhD; Margaret Yu, MD

Identifying small molecule drugs for the treatment of immune-mediated diseases using transgenic zebrafish

Principal Investigator: Nikolaus Trede, MD, PhD

Department: Pediatrics

Collaborators: Frank Fitzpatrick, PhD; Gerald Spangrude, PhD

Last Modified: Tuesday, April 24, 2007

footer

HOME  :  SITE MAP  :  HELP  :  CONTACT US  :  DISCLOSURE  :  PRIVACY STATEMENT

Huntsman Cancer Institute operates a hospital-based patient care center in association with
the Health Sciences Center at the University of Utah.

University of Utah disclaimer.

Copyright © 2008, all rights reserved, Huntsman Cancer Institute.